Author/Authors :
Pałgan ,Krzysztof Department of Allergy - Clinical Immunology and Internal Medicine - Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland , Żbikowska-Götz, Magdalena Department of Allergy - Clinical Immunology and Internal Medicine - Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland , Lis, Kinga Department of Allergy - Clinical Immunology and Internal Medicine - Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland , Chrzaniecka, Elżbieta Department of Allergy - Clinical Immunology and Internal Medicine - Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland , Bartuzi, Zbigniew Department of Allergy - Clinical Immunology and Internal Medicine - Collegium Medicum in Bydgoszcz - Nicolaus Copernicus University in Torun, Poland
Abstract :
Introduction
Asthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.
Aim
To analyse forced expiratory volume in 1 s (FEV1) following the adminstration of omalizumab.
Material and methods
Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.
Results
Treatment with omalizumab increased in all subjects FEV1 by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.
Conclusions
These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.
Keywords :
asthma , omalizumab , spirometry , forced expiratory volume in 1 s
